NMB

National Mango Board Welcomes New Executive Director

Retrieved on: 
Monday, July 17, 2023
Growth, NMB, Life, Management

ORLANDO, Fla., July 17, 2023 /PRNewswire/ -- Today the National Mango Board (NMB) announced the appointment of Ramon Ojeda as its new executive director. This transition occurs nine years after Manuel Michel accepted his position to lead the organization.

Key Points: 
  • ORLANDO, Fla., July 17, 2023 /PRNewswire/ -- Today the National Mango Board (NMB) announced the appointment of Ramon Ojeda as its new executive director.
  • His previous experience, paired with his passion for the mango industry, will serve him well as the new executive director.
  • "Serving the mango industry in the lead role as NMB's executive director is an incredible opportunity and a true honor for me," said Ramon Ojeda.
  • "I wish Ramon and the National Mango Board all the best and continued success as I move into this next chapter in life.

Baudax Bio Acquires TeraImmune, Inc.

Retrieved on: 
Friday, June 30, 2023
HA, Drug discovery, Plasma protein binding, NMB, Organ transplantation, MS, Acquisition, Patient, VIII, Entrepreneurship, FDA, Haemophilia A, Pemphigus vulgaris, IND, Treatment, Pharmaceutical industry, Myasthenia gravis, Doctor of Philosophy

MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) --  Baudax Bio, Inc. (Nasdaq:BXRX) (“Baudax Bio” or the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, today announced the acquisition of TeraImmune, a privately held a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases.

Key Points: 
  • “This combination blends the world class scientific expertise of the TeraImmune team with the Baudax team’s proven ability to execute clinical development programs, which we believe is a win for the shareholders of both companies,” said Ms. Henwood.
  • “This merger adds TeraImmune’s TI-168 asset to the Baudax portfolio—a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate clotting factor VIII (FVIII) inhibitors in Hemophilia A patients.
  • “We are looking forward to working with Gerri Henwood and the excellent clinical development team at Baudax to advance this asset to its full potential,” said Jihoon (Jay) Park, PhD, Co-Founder of TeraImmune.
  • In conjunction with the transaction, Yong Chan Kim, Ph D, former Chief Executive Officer of TeraImmune, will be appointed to the Board of Directors of Baudax.

SWAPA Requests Release from the National Mediation Board

Retrieved on: 
Thursday, June 29, 2023
Railway Labor Act, Aircraft pilot, NMB, National Mediation Board, Bleeding, RLA, Negotiation, Aircraft, Airline

DALLAS, June 29, 2023 /PRNewswire/ -- Today, the Southwest Airlines Pilots Association (SWAPA) filed a request with the National Mediation Board (NMB) to be officially released from mediation.

Key Points: 
  • DALLAS, June 29, 2023 /PRNewswire/ -- Today, the Southwest Airlines Pilots Association (SWAPA) filed a request with the National Mediation Board (NMB) to be officially released from mediation.
  • SWAPA and Southwest have been in negotiations for a new contract for more than three years and in federal mediation since September 2022.
  • SWAPA negotiators have become increasingly frustrated with Southwest's lack of commitment to negotiating in earnest and the pace of productivity during this negotiation cycle.
  • "If released from mediation, our Pilot group will continue down the path afforded to us through the Railway Labor Act (RLA)," said SWAPA President Casey Murray.

Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000

Retrieved on: 
Wednesday, June 7, 2023
Good, ED95, Bromide, Arm, Plasma protein binding, Clinical trial, EMG, NMB, Electromyography, MD, Patient, Safety, Anesthesiology, Pharmaceutical industry, Anesthesia

Additional analyses of electromyography (EMG) of neuromuscular blockade confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium.

Key Points: 
  • Additional analyses of electromyography (EMG) of neuromuscular blockade confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium.
  • The BX1000 Phase 2 surgery trial was a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a completed clinical trial of 80 adult patients who had elective surgery utilizing total intravenous anesthesia.
  • A total of 81 patients were randomized to the four treatment groups.
  • Additionally, the clinical trial evaluated the safety and tolerability profile of BX1000 and rocuronium in this patient population.

For A Bright Future Foundation Unveils Revolutionary Media Lab Program at North Miami Beach Discovery Library in Florida, Paving the Way for Future Media Professionals

Retrieved on: 
Wednesday, June 7, 2023
Workforce, Media lab, Aalto Media Lab, STEAM, FABF, The arts, Student, Education, Life, Curriculum, NMB, Science, technology, engineering, and mathematics, Blackmagic Design, Envoi, Allison Academy School (North Miami Beach, Florida), School, Black Magic, Bright Futures Scholarship Program, Ecosystem, St. John Bosco High School, Management, Television, Science, Mathematics, Engineering, Lenovo

MIAMI, June 7, 2023 /PRNewswire/ -- Louis Hernandez Jr.'s Foundation For A Bright Future ("For a Bright Future," "FABF"), a 501(c)(3) nonprofit organization dedicated to supporting underserved children through education and healthcare initiatives, has launched its innovative Media Lab program at the North Miami Beach ("NMB") Discovery Library in Florida, with the support of key partners in media technology. This unique program aims to make Science, Technology, Engineering, the Arts, and Mathematics (STEAM) education more accessible and help prepare students for a bright future.

Key Points: 
  • The Media Lab is an initiative and hands-on experience for high school students to develop essential skills and engagement in the media space.
  • Our collaborations with schools and academic institutions like the North Miami Beach Discovery Library present an opportunity for driven students to immerse themselves in media technology.
  • "For A Bright Future Media Lab program will not only inspire the next generation of media professionals, but also create new educational and job opportunities in the industry.
  • Together, we can make a lasting impact on the world," said Gary Bettan, Chair of the Media Lab Committee, FABF.

Baudax Bio Reports First Quarter Financial Results and Provides Business Update

Retrieved on: 
Friday, May 12, 2023
Transfer, Purchasing, IV, Anesthesiology, New Drug Application, Plasma protein binding, DRS, See, Associate, Development, Agent, Patient, National Association, Three Months, PSA, Amendment, Wilmington Trust, Credit agreements in South Africa, EMG, Pharmacokinetics, ATLA, Teenage Mutant Ninja Turtles (2003 TV series, season 6), IND, The Transfer Agreement, Safety, Volunteering, Bromide, NMB, University, Clinical research, Research, Good, National Railway Company of Belgium, Reversal, Series, Intubation, Perioperative medicine, Pharmaceutical industry, Vaccine, Birth control, Security (finance), Cryptocurrency, Asset, Anesthesia, Credit, Alkermes, Creditor

MALVERN, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the quarter ended March 31, 2023, and provided a business update.

Key Points: 
  • MALVERN, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the quarter ended March 31, 2023, and provided a business update.
  • Baudax Bio expects to complete nonclinical studies and manufacturing data required to support the IND for BX3000 in late summer of 2023.
  • Financial Results for the Three Months Ended March 31, 2023
    As of March 31, 2023, Baudax Bio had cash and cash equivalents of $3.8 million.
  • Baudax Bio reported net loss from continuing operations of $(7.4) million, or $(3.19) per share, for the three months ended March 31, 2023.

Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000

Retrieved on: 
Tuesday, April 25, 2023
Good, Bromide, Arm, Anesthesiology, National Railway Company of Belgium, Plasma protein binding, Clinical trial, NMB, Associate, Patient, University, Clinical research, Intubation, Perioperative medicine, Safety, New Drug Application, Pharmaceutical industry, Anesthesia

MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced positive top-line results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. Results of the study showed that BX1000 met the primary endpoint of readiness for intubation (evaluated as “Good” or “Excellent”) at all dose levels assessed. No severe adverse events were observed in any dose regimen.

Key Points: 
  • MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced positive top-line results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.
  • Results of the study showed that BX1000 met the primary endpoint of readiness for intubation (evaluated as “Good” or “Excellent”) at all dose levels assessed.
  • The BX1000 Phase 2 surgery trial is a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a planned clinical trial of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.
  • Additionally, the clinical trial evaluated the safety and tolerability profile of BX1000 and rocuronium in this patient population.

Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial

Retrieved on: 
Monday, April 24, 2023
Faculty, Bromide, University, American Board of Anesthesiology, Plasma protein binding, Uniformed Services University of the Health Sciences, Clinical trial, NMB, Associate, American Board of Commissioners for Foreign Missions, Memorial Hermann–Texas Medical Center, MD, Wilford Hall Ambulatory Surgical Center, Patient, Clinical research, Internal medicine, Fellow, Pain management, Outline of health sciences, Texas Medical Center, Air force, Perioperative medicine, Hospital, Principal, University of the Witwatersrand, FDA, Research, United States Department of the Air Force, Pharmaceutical industry, Dentistry, Anesthesiology, Analgesic, Anesthesia

The BX1000 Phase 2 surgery trial is a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a planned trial of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.

Key Points: 
  • The BX1000 Phase 2 surgery trial is a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a planned trial of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.
  • A live question and answer session will follow the formal presentations.
  • Todd M Bertoch, MD, is a diplomate of the American Board of Anesthesiology.
  • After receiving his Fellowship in the Faculty of Anesthesiologists in South Africa, he relocated to the Texas Medical Center in Houston.

EL CAR WASH ANNOUNCES THE ACQUISITION AND RE-OPENING OF SMART CAR WASH NORTH MIAMI BEACH AND WEST PALM BEACH

Retrieved on: 
Tuesday, April 4, 2023
Palm Beach Gardens, Florida, NMB, ECW, North Miami Beach, Florida, LED, Acquisition, Love, Water, Baptist Health, Miami, WPB, Glass, Compressed air, Nightclub

MIAMI, April 4, 2023 /PRNewswire/ -- El Car Wash ("ECW"), the largest and fastest growing car wash operator in Florida, completed the acquisition of Smart Car Wash and its North Miami Beach and West Palm Beach locations.

Key Points: 
  • MIAMI, April 4, 2023 /PRNewswire/ -- El Car Wash ("ECW"), the largest and fastest growing car wash operator in Florida, completed the acquisition of Smart Car Wash and its North Miami Beach and West Palm Beach locations.
  • El Car Wash is known for its prime locations, great customer service, high quality operations, distinctive aesthetic and industry leading membership program.
  • The Company is also the Official Car Wash of the Miami HEAT and a partner of Baptist Health and Zoo Miami.
  • El Car Wash invested substantial capital to upgrade the Smart Car Wash stores and convert them to the El Car Wash brand.

Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000

Retrieved on: 
Monday, March 27, 2023
Good, Bromide, Clinical trial, NMB, Patient, Plasma protein binding, Intubation, Safety, Pharmaceutical industry

MALVERN, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced positive results from the second preplanned interim analysis of its Phase 2 trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.

Key Points: 
  • The BX1000 Phase 2 surgery trial is a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a planned trial of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.
  • The primary efficacy endpoint is the proportion of patients meeting criteria for Good or Excellent intubating conditions using a standardized scale.
  • Additionally, the clinical trial is evaluating the safety and tolerability profile of BX1000 and rocuronium in this patient population.
  • We anticipate completing enrollment in this trial soon, and announcing top line results in late April or early May.”